|
National Right to Life Praises the Food and Drug Commissioner for Planned Review of the Abortion Drug Mifepristone
WASHINGTON -- The National Right to Life Committee (NRLC) praised the U.S. Food and Drug Administration (FDA) Commissioner, Dr. Marty Makary, for his planned review of the abortion pill mifepristone.
National Right to Life released a letter the organization sent to FDA Commissioner Dr. Marty Makary on May 29, 2025, asking for a review of the abortion drug in light of new studies showing its frequent association with serious, often life-threatening adverse events.
“The FDA owes it to the American people—especially to women—to reconsider the standards under which this drug was approved and is currently being distributed,”said Carol Tobias, president of National Right to Life. “Women deserve the truth about the risks associated with abortion pills.”
Tobias continued, “At the very least, the agency should reinstate pre-2016 safety protocols, including in-person physician oversight, an earlier gestational cutoff, and full adverse event reporting.”
NRLC’s letter calls for a full review of the FDA’s approval and deregulation of mifepristone and an immediate halt to online and pharmacy distribution of the drug, pending a complete reevaluation of its safety profile. This followed a new study by the Ethics and Public Policy Center (EPPC) revealing serious safety concerns at nearly 22 times the rate reported by the abortion industry’s sponsored studies.
“This is a matter of public health and ethical responsibility,” said Tobias.
Read the full release here.
Read the full letter from NRLC to the FDA Commissioner here.
| 
